Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe conducted a matched case-control study among all individuals eligible for sotrovi...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Ahmed, Zaqout (author)
مؤلفون آخرون: Almaslamani, Muna A. (author), Chemaitelly, Hiam (author), Hashim, Samar A. (author), Ittaman, Ajithkumar (author), Alimam, Abeir (author), Rustom, Fatma (author), Daghfal, Joanne (author), Abukhattab, Mohammed (author), AlMukdad, Sawsan (author), Kaleeckal, Anvar Hassan (author), Latif, Ali Nizar (author), Butt, Adeel A. (author), Bertollini, Roberto (author), Al-Khal, Abdullatif (author), Omrani, Ali S. (author), Abu-Raddad, Laith J. (author)
التنسيق: article
منشور في: 2022
الموضوعات:
COVID-19
SARS-CoV-2
Sotrovimab
Omicron
BA.2
Epidemiology
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.ijid.2022.09.023
https://www.sciencedirect.com/science/article/pii/S1201971222005227
http://hdl.handle.net/10576/45351
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا

مواد مشابهة